scholarly journals The Wilms' Tumor Gene Product (WT1) Modulates the Response to 1,25-Dihydroxyvitamin D3by Induction of the Vitamin D Receptor

2000 ◽  
Vol 276 (6) ◽  
pp. 3727-3732 ◽  
Author(s):  
Ulrich Maurer ◽  
Frederic Jehan ◽  
Christoph Englert ◽  
Gabriele Hübinger ◽  
Eckhart Weidmann ◽  
...  
Keyword(s):  
Vitamin D ◽  
Gene Product ◽  
Vitamin D Receptor ◽  
Wilms Tumor ◽  
Wilms Tumor Gene ◽  
Tumor Gene

Transcriptional repression mediated by the WT1 Wilms tumor gene product

Science ◽  
1991 ◽  
Vol 253 (5027) ◽  
pp. 1550-1553 ◽  
Author(s):  
S. Madden ◽  
D. Cook ◽  
J. Morris ◽  
A Gashler ◽  
V. Sukhatme ◽  
...  
Keyword(s):  
Gene Product ◽  
Transcriptional Repression ◽  
Wilms Tumor ◽  
Wilms Tumor Gene ◽  
Tumor Gene

scholarly journals Value of Wilms tumor gene product (WT-1) immunohistochemical expression in ovarian neoplasms

2014 ◽  
Vol 2 (1) ◽  
Author(s):  
Amal Abd El hafez ◽  
Ibrahim E l-dosoki ◽  
Soheir Sirag ◽  
Asmaa Gado ◽  
Adel Denewer
Keyword(s):  
Gene Product ◽  
Ovarian Neoplasms ◽  
Wilms Tumor ◽  
Immunohistochemical Expression ◽  
Wilms Tumor Gene ◽  
Tumor Gene

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS

Blood ◽  
2009 ◽  
Vol 113 (26) ◽  
pp. 6541-6548 ◽  
Author(s):  
Ulrich Keilholz ◽  
Anne Letsch ◽  
Antonia Busse ◽  
Anne Marie Asemissen ◽  
Sandra Bauer ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Gene Product ◽  
Wilms Tumor ◽  
Keyhole Limpet Hemocyanin ◽  
Refractory Anemia ◽  
Median Frequency ◽  
Mrna Levels ◽  
Peptide Vaccination ◽  
Wilms Tumor Gene ◽  
Tumor Gene

Abstract This study investigated the immunogenicity of Wilms tumor gene product 1 (WT1)–peptide vaccination in WT1-expressing acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients without curative treatment option. Vaccination consisted of granulocyte-macrophage colony-stimulating factor subcutaneously days 1 to 4, and WT1.126-134 peptide and 1 mg keyhole limpet hemocyanin on day 3. The initial 9 patients received 4 vaccinations biweekly, then monthly, and the subsequent 10 patients received continual biweekly vaccination. Seventeen AML patients and 2 refractory anemia with excess blasts patients received a median of 11 vaccinations. Treatment was well tolerated. Objective responses in AML patients were 10 stable diseases (SDs) including 4 SDs with more than 50% blast reduction and 2 with hematologic improvement. An additional 4 patients had clinical benefit after initial progression, including 1 complete remission and 3 SDs. WT1 mRNA levels decreased at least 3-fold from baseline in 35% of patients. In 8 of 18 patients, WT1-tetramer+ T cells increased in blood and in 8 of 17 patients in bone marrow, with a median frequency in bone marrow of 0.18% at baseline and 0.41% in week 18. This WT1 vaccination study provides immunologic, molecular, and preliminary evidence of potential clinical efficacy in AML patients, warranting further investigations.

Wilms Tumor Gene Product

2004 ◽  
pp. 122-126 ◽  
Author(s):  
Harry Hwang ◽  
Louise Quenneville ◽  
Hadi Yaziji ◽  
Allen M. Gown
Keyword(s):  
Gene Product ◽  
Wilms Tumor ◽  
Wilms Tumor Gene ◽  
Tumor Gene

scholarly journals The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun

Oncogene ◽  
1999 ◽  
Vol 18 (20) ◽  
pp. 3143-3151 ◽  
Author(s):  
Valérie Dejong ◽  
Armelle Degeorges ◽  
Stéphanie Filleur ◽  
Slimane Ait-Si-Ali ◽  
Amel Mettouchi ◽  
...  
Keyword(s):  
Gene Product ◽  
Wilms Tumor ◽  
Wilms Tumor Gene ◽  
Thrombospondin 1 ◽  
Tumor Gene
Sign in / Sign up

Export Citation Format

Share Document